This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Sir Gregory Winter | |
|---|---|
| Name | Gregory Winter |
| Honorific prefix | Sir |
| Birth date | 14 April 1951 |
| Birth place | Leek, Staffordshire, England |
| Fields | Biochemistry, Molecular Biology, Protein Engineering |
| Workplaces | University of Cambridge; Medical Research Council Laboratory of Molecular Biology; MRC Centre for Protein Engineering; Cambridge Antibody Technology; Domantis; Bicycle Therapeutics; AstraZeneca |
| Alma mater | University of Cambridge; University of Cambridge (PhD) |
| Doctoral advisor | Richard J. H. Goodwin |
| Known for | Phage display; humanization of antibodies; therapeutic antibodies such as adalimumab |
| Awards | Nobel Prize in Chemistry (2018); Royal Medal; Copley Medal; Knight Bachelor |
Sir Gregory Winter is a British biochemist and molecular engineer noted for pioneering methods to create humanized and fully human therapeutic antibodies using phage display and directed evolution. He led work translating molecular biotechnology into clinical treatments, founding companies and partnering with pharmaceutical firms to develop medicines for autoimmune disease, cancer, and infectious disease. His career spans academic leadership at the Medical Research Council and entrepreneurial roles in biotechnology, culminating in recognition including the Nobel Prize in Chemistry.
Born in Leek, Staffordshire, he attended Repton School and studied natural sciences at Trinity College, Cambridge where he read Biochemistry. He undertook doctoral research at the University of Cambridge under the supervision of Richard Goodwin, focusing on immunoglobulin gene organization and antibody structure at the Laboratory of Molecular Biology. His graduate training placed him amid researchers associated with the Medical Research Council and contemporaries linked to achievements at the MRC Laboratory of Molecular Biology, Cambridge University and the emergent biotechnology sector in Cambridge, England.
He established the MRC Centre for Protein Engineering in Cambridge and served as its director, linking academic programmes at the University of Cambridge with translational efforts involving Cambridge Antibody Technology and later companies such as Domantis and Cambridge BioMedical Campus collaborators. His laboratory developed phage display technology derived from earlier work by George P. Smith and influenced by studies by Sir César Milstein and Niels Kaj Jerne on antibody diversity; those technological advances intersected with intellectual property managed by institutions like Wellcome Trust and collaborations with pharmaceutical companies including AbbVie and AstraZeneca. He trained and collaborated with scientists who later moved to institutions such as Harvard University, Stanford University, Massachusetts Institute of Technology, European Molecular Biology Laboratory, and industry groups at Genentech and Amgen.
His career combined bench science with organizational leadership, engaging with funding bodies like the Biotechnology and Biological Sciences Research Council, participating in biotechnology ventures that interacted with markets represented by London Stock Exchange and NASDAQ listings. His laboratory produced work cited alongside discoveries from teams at Cold Spring Harbor Laboratory, Max Planck Institute, and Scripps Research Institute.
He applied directed evolution principles inspired by concepts from Charles Darwin and laboratory evolution approaches advanced by Frances Arnold to the engineering of antibody fragments displayed on bacteriophage, building on phage genetics from Niels K. Jerne-influenced frameworks and the bacteriophage research of Felix d'Herelle-era lines. Using phage display libraries, his teams humanized murine monoclonal antibodies first generated by hybridoma work associated with César Milstein and Geoffrey Köhler and advanced fully human antibodies by selecting human antibody fragments from combinatorial libraries, thereby enabling clinical candidates such as adalimumab developed in partnership with Abbott Laboratories (now AbbVie). These technologies led to therapeutics targeting tumor necrosis factor pathways approved for conditions treated by clinicians at institutions like Mayo Clinic and Johns Hopkins Hospital.
His directed evolution approaches influenced subsequent protein engineering work at companies such as Genentech, Amgen, Roche, and academic groups at Imperial College London and University College London. The methods enabled generation of antibody–drug conjugates, bispecific antibodies, and fragment-based scaffolds used by firms including Bicycle Therapeutics and Domantis, and fed into collaborations with regulatory agencies such as the European Medicines Agency and United States Food and Drug Administration for clinical development and approval pathways.
He was knighted as a Knight Bachelor and received numerous scientific distinctions including the Nobel Prize in Chemistry (2018, shared with Frances Arnold and George P. Smith), the Royal Medal from the Royal Society, and the Copley Medal. He is a Fellow of the Royal Society and a Fellow of Trinity College, Cambridge, and has been recognized by bodies such as the Royal Society of Chemistry, European Molecular Biology Organization, Academia Europaea, and the American Academy of Arts and Sciences. His awards intersect with honours granted by universities including University of Oxford, University of Edinburgh, University of York, and international institutes like ETH Zurich.
Outside the laboratory, he has been involved with philanthropic organisations including the Wellcome Trust and charitable activities tied to medical research at the Cambridge Biomedical Campus and support for translational science programmes at institutions such as Imperial College London and King's College London. He has served on advisory boards and governance bodies connected to the Medical Research Council and private foundations in the United Kingdom and internationally. He maintains connections to academic mentoring networks around Cambridge, contributing to initiatives that bridge university research and industry spinouts listed on exchanges including the London Stock Exchange and NASDAQ.
Category:British biochemists Category:Nobel laureates in Chemistry Category:Fellows of the Royal Society